Clinical Trials

23 enrolled

Anus Neoplasms

NCT05733689 2026-03-10

Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

20 enrolled

Gastroesophageal Adenocarcinoma

NCT03174275 2026-02-23

Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma

GastrointestinalHead & Neck

39 enrolled 8 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Esophageal Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT07403435 2026-02-11

Short-course Radiotherapy Combined With Serplulimab and Chemotherapy as Neoadjuvant Treatment for Resectable ESCC

22 enrolled

Esophageal Squamous Cell Carcinoma

NCT03801876 2026-01-14

Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Phase 3 Recruiting

300 enrolled

Phase 1 Active not recruiting

Clinical Stage I Esophageal Adenocarcinoma AJCC v8

NCT02213497 2026-01-08

Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer

30 enrolled

Esophageal Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT07317609 2026-01-05

Endosurgery-02

60 enrolled

Phase 3 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT07306663 2025-12-29

ESO-Nanjing7

242 enrolled

Esophageal Neoplasms

NCT02297217 2025-12-16

PaRCUS

50 enrolled

Esophageal Neoplasms

NCT07266493 2025-12-05

Efficacy and Safety of Neoadjuvant Envafolimab Combined With Albumin-bound Paclitaxel and Carboplatin for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

26 enrolled

Esophageal Squamous Cell Carcinoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma

NCT05189730 2025-11-20

ETNT

80 enrolled

Esophageal Squamous Cell Carcinoma

NCT04656041 2025-11-14

Folfox+Irinotecan+Chemort In Esophageal Cancer

40 enrolled

Gastroesophageal Junction Adenocarcinoma

NCT04615013 2025-10-30

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

GastrointestinalGynecologic

24 enrolled

Cervical Esophagus Adenocarcinoma

NCT04954599 2025-10-07

Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI

Phase 1/2 Recruiting

126 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

NCT03110926 2025-09-12

Induction Chemotherapy for Locally Advanced Esophageal Cancer

40 enrolled

Esophageal Neoplasms

NCT04929392 2025-09-04

Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer

3 enrolled

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma

NCT05880082 2025-08-24

PPIO-004-EC001

118 enrolled

Phase 1/2 Enrolling by invitation

Esophageal Squamous Cell Carcinoma

NCT05385861 2025-08-15

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

52 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

NCT04268121 2025-07-23

NEONEC

EndocrineGastrointestinal

78 enrolled

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT04046575 2025-07-11

Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer

Phase 1 Active not recruiting

12 enrolled

Esophageal Neoplasms

NCT02730546 2025-06-22

Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery

Phase 1/2 Completed

31 enrolled 20 charts

Phase 3 Enrolling by invitation

Stomach Neoplasms

NCT07016737 2025-06-12

ESO-Nanjing12

79 enrolled

Esophageal Squamous Cell Carcinoma

NCT06839105 2025-05-31

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

DermatologicGastrointestinalGenitourinaryThoracic

214 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Colorectal Neoplasms

NCT04478292 2025-05-18

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

Phase 3 Recruiting

330 enrolled

Hepatoblastoma

NCT06861894 2025-05-15

Active Surveillance After Neoadjuvant Adebrelimab Combined With Chemoradiotherapy for Resectable ESCC

164 enrolled

Esophageal Squamous Cell Carcinoma

NCT06965829 2025-05-11

The Effect of Neoadjuvant Chemoimmnotherapy Combined With Node Sparing Radiotherapy for cT3N+ EC

40 enrolled

Esophageal Neoplasms

NCT06637163 2025-04-17

Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC

100 enrolled

Phase 1 Active not recruiting

Esophageal Squamous Cell Carcinoma

NCT03044613 2025-03-06

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

32 enrolled

Phase EARLY_PHASE1 Terminated

Esophageal Neoplasms, Stomach Neoplasms

NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

2 enrolled

GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

NCT00780494 2025-01-14

Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma

35 enrolled 13 charts

GastrointestinalSarcoma

Stomach Neoplasms, Gastrointestinal Stromal Tumors

NCT03980925 2025-01-13

Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.

EndocrineGastrointestinalNET

37 enrolled 25 charts

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

NCT06599775 2024-09-19

Study of Adebrelimab With Chemotherapy, Endoscopy and Sequential Chemoradiotherapy In Inoperable Esophageal Cancer

42 enrolled

Resectable Esophageal Squamous Cell Carcinoma

NCT03490292 2024-07-26

Avelumab With Chemoradiation for Stage II/III Resectable Esophageal and Gastroesophageal Cancer

Phase 1/2 Completed

22 enrolled 17 charts

Resectable Esophageal Cancer

NCT04481256 2024-07-26

TAPESTRY

Phase NA Recruiting

49 enrolled

Carcinoma, Squamous Cell, Esophageal Neoplasms

NCT06084897 2024-06-14

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

120 enrolled

Phase 3 Active not recruiting

Esophageal Neoplasms

NCT03017326 2024-05-13

PHITT

450 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular, Hepatoblastoma

NCT02509286 2024-05-08

ESOPEC

438 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms

NCT06403878 2024-05-08

Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer

68 enrolled

Esophageal Neoplasms

NCT02931890 2024-05-02

CRITICS-II

207 enrolled

Stomach Neoplasms

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

Phase 1/2 Completed

73 enrolled 18 charts

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT01505569 2024-02-26

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors

Phase NA Completed

44 enrolled

CNSGastrointestinalGenitourinaryOther solid neoplasmSarcoma

Brain Neoplasms, Carcinoma, Renal Cell, Medulloblastoma, Neoplasms, Germ Cell and Embryonal, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Rhabdoid Tumor

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT04568200 2024-01-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Resectable Esophageal Squamous Cell Carcinoma

60 enrolled

Esophageal Squamous Cell Carcinoma

NCT02735057 2024-01-18

OSAGE

Phase 1/2 Recruiting

54 enrolled

Esophageal Neoplasms

NCT02037048 2024-01-08

FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma

Phase 2 Unknown

63 enrolled

Adenocarcinoma Of Esophagus, Esophageal Neoplasms

NCT00486356 2024-01-03

Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer

Phase 1 Completed

46 enrolled